CA-C3.AI/NCS
17.6.2021 06:02:07 CEST | Business Wire | Press release
C3 AI (NYSE:AI), the Enterprise AI application software company, and NCS, a leading technology services provider and member of the Singtel Group, today announced a strategic partnership focused on delivering enterprise AI solutions to clients in Southeast Asia (SEA) and Australia/New Zealand (ANZ) across multiple industries, including telecommunications, government, financial services, transportation, and more.
This agreement represents C3 AI’s first strategic partnership with a telecommunications group. NCS will leverage its deep domain experience and technology expertise in serving governments and businesses in SEA and ANZ, investing up to S$10 million to develop and deploy enterprise AI applications created on the C3 AI® Suite. C3 AI’s solutions will also be deployed across Singtel, Optus, and other affiliated telecommunications networks to bring the advantages of enterprise AI to their operations and clients.
As the leader in enterprise AI applications, C3 AI’s offerings include the C3 AI Suite, a powerful end-to-end enterprise AI platform; C3 AI Ex Machina, a no-code solution that anyone can use to generate actionable enterprise AI insights; C3 AI CRM, the first enterprise AI-powered CRM solution custom-built for industries; and a comprehensive inventory of pre-built enterprise AI applications. These applications cover a broad range of use cases, such as C3 AI Energy Management for optimizing energy consumption and carbon emissions, C3 AI Predictive Maintenance to reduce unplanned machine downtime, and C3 AI Fraud Detection for financial transactions.
“Our partnership with C3 AI reaffirms NCS’ commitment to build a strong digital partner ecosystem that provides our clients access to world-leading technologies and enterprise solutions,” said NCS CEO Ng Kuo Pin. “We believe that the wave of enterprise-grade AI solutions has arrived and are excited to work with our clients to build the next generation of digital applications with enterprise AI embedded. We look forward to playing our part to unleash the transformative power of enterprise AI across governments and enterprises in Asia-Pacific.”
In its 2021 Global CIO Agenda survey, Gartner found that SEA and ANZ were among the fastest-growing regions in the world to apply digitalization to optimize enterprise processes1 . In addition, CIOs in these regions identified Artificial Intelligence/Machine Learning as a game-changing technology2 . To capitalize on this trend, C3 AI and NCS will establish a Center of Excellence together to jointly explore new solutions that will accelerate the adoption of enterprise AI and develop custom-built offerings tailored to the business requirements of the Asia-Pacific market.
“Our Center of Excellence will bring together experts from C3 AI and NCS to carefully study and respond to the specific needs of organizations and industries in Southeast Asia, Australia, and New Zealand,” said General Manager, Industries and Alliances at C3 AI Gene Reznik. “This will allow us to better serve customers in SEA and ANZ and provide them with the enterprise AI solutions they require to achieve their digital transformation objectives.”
“Singtel and NCS are clear leaders in the deployment and implementation of telecommunication and cloud solutions, and we are incredibly excited to be joining forces with such a respected and forward-looking partner,” said C3 AI Chairman and CEO Thomas M. Siebel. “NCS’ focus on digital transformation will help drive enterprise AI in Asia-Pacific, especially in the telecommunications industry, on a massive scale.”
1 Gartner, '2021 CIO Agenda: Global Perspectives on 'Seize This Opportunity for Digital Business Acceleration', Andy Rowsell-Jones, Tomas Neilsen, Jan-Martin Lowendahl, Chris Howard, Monika Sinha, March 05, 2021
2 Gartner, '2021 CIO Agenda: A Southeast Asia Perspective', Adrian Lee, February 03, 2021; Gartner, '2021 CIO Agenda: An Australia and New Zealand Perspective', Andy Rowsell-Jones, Brian Ferreira, Christopher Bell, December 15, 2021
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About NCS
NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of Applications, Infrastructure and Engineering. NCS also believes in building a strong partner eco-system with leading technology players and research institutions to support open innovation and co-creation.
For more information, please visit www.ncs.com.sg .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616006026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom